- Home
- BCML vs CLLS Comparison
BCML vs CLLS Comparison
Compare BCML & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCML | CLLS |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.1M | 485.6M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | BCML | CLLS |
|---|---|---|
| Price | $29.69 | $4.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $32.00 | $8.50 |
| AVG Volume (30 Days) | 22.6K | ★ 112.6K |
| Earning Date | 01-22-2026 | 11-07-2025 |
| Dividend Yield | ★ 3.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $94,896,000.00 | $82,551,000.00 |
| Revenue This Year | $0.51 | $32.58 |
| Revenue Next Year | $10.33 | $20.68 |
| P/E Ratio | $14.47 | ★ N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $22.22 | $1.10 |
| 52 Week High | $33.15 | $5.48 |
Technical Indicators
Market Signals| Indicator | BCML | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 54.48 |
| Support Level | $29.41 | $4.47 |
| Resistance Level | $33.15 | $5.03 |
| Average True Range (ATR) | 1.08 | 0.28 |
| MACD | -0.23 | -0.02 |
| Stochastic Oscillator | 43.57 | 54.55 |
Price Performance
Historical ComparisonAbout BCML BayCom Corp
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.